(Q47375821)

15 January 2018

title

Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model (English)

1 reference

15 January 2018

1 reference

1 reference

1 reference

1

1 reference

15 January 2018

Chantal Csajka

4

1 reference

15 January 2018

Andrew Owen

9

1 reference

15 January 2018

author name string

L Almond

2

1 reference

15 January 2018

A Schipani

3

1 reference

15 January 2018

C Marzolini

5

1 reference

15 January 2018

C Wyen

6

1 reference

15 January 2018

N H Brockmeyer

7

1 reference

15 January 2018

M Boffito

8

1 reference

15 January 2018

D Back

10

1 reference

15 January 2018

language of work or name

English

0 references

publication date

18 July 2012

1 reference

15 January 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

15 January 2018

volume

92

1 reference

15 January 2018

issue

4

1 reference

15 January 2018

page(s)

494-502

1 reference

15 January 2018

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Successful efavirenz dose reduction guided by therapeutic drug monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Higher efavirenz plasma levels correlate with development of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Simulation and prediction of in vivo drug metabolism in human populations from in vitro data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

The Simcyp population-based ADME simulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Population approaches/sparse data analysis for human variability in kinetics and dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Induction of multiple drug transporters by efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

Pharmacokinetic Parameters of Nevirapine and Efavirenz in Relation to Antiretroviral Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

7 January 2021

Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

7 January 2021

Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

7 January 2021

Determination of the pKa and pH-solubility behavior of an ionizable cyclic carbamate, (S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4- (trifluoromethyl)-2H-3,1-benzoxazin-2-one (DMP 266)

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.61

7 January 2021

Identifiers

DOI

10.1038/CLPT.2012.61

1 reference

15 January 2018

1 reference

15 January 2018